+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2021

  • ID: 4989065
  • Clinical Trials
  • July 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Axium Pharmaceuticals
  • CuroNZ
  • Marinus Pharmaceuticals
  • SK biopharmaceuticals
  • TAHO Pharmaceuticals
  • Takeda
  • MORE
This Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2021 provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lennox-Gastaut Syndrome (LGS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Lennox-Gastaut Syndrome (LGS) Understanding


Lennox-Gastaut Syndrome (LGS): Overview


Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Children with Lennox-Gastaut syndrome may also develop cognitive dysfunction, delays in reaching developmental milestones and behavioral problems. The symptoms of Lennox-Gastaut syndrome usually begin during infancy or childhood, most often between 3 to 5 years of age. Most affected individuals experience multiple types of seizures, multiple times throughout the day. A diagnosis of Lennox-Gastaut syndrome is usually made based upon a thorough clinical evaluation, a detailed patient history and a complete physical and neurological evaluation including advanced imaging techniques, such as electroencephalography (EEG) and magnetic resonance imaging (MRI). The three main forms of treatment of Lennox-Gastaut syndrome are anti-epileptic drugs (AEDs), dietary therapy (typically the ketogenic diet) or device/surgery (VNS therapy or corpus callosotomy). Rarely, resective surgery is an option.

Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lennox-Gastaut Syndrome (LGS) pipeline landscape is provided which includes the disease overview and Lennox-Gastaut Syndrome (LGS) treatment guidelines. The assessment part of the report embraces, in depth Lennox-Gastaut Syndrome (LGS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lennox-Gastaut Syndrome (LGS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Lennox-Gastaut Syndrome (LGS) R&D. The therapies under development are focused on novel approaches to treat/improve Lennox-Gastaut Syndrome (LGS).

Lennox-Gastaut Syndrome (LGS) Emerging Drugs Chapters


This segment of the Lennox-Gastaut Syndrome (LGS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lennox-Gastaut Syndrome (LGS) Emerging Drugs


Soticlestat: Takeda

Soticlestat is a potent, highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). In March 2021, Takeda Pharmaceutical Company and Ovid Therapeutics announced that Takeda has entered into an exclusive agreement under which Takeda secured global rights at closing from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet Syndrome and Lennox-Gastaut syndrome (LGS). The drug is in Phase III clinical studies for the treatment of Lennox-Gastaut Syndrome (LGS).

Lennox-Gastaut Syndrome (LGS): Therapeutic Assessment


This segment of the report provides insights about the different Lennox-Gastaut Syndrome (LGS) drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Lennox-Gastaut Syndrome (LGS)


There are approx. 7+ key companies which are developing the therapies for Lennox-Gastaut Syndrome (LGS). The companies which have their Lennox-Gastaut Syndrome (LGS) drug candidates in the most advanced stage, i.e. Phase III include, Takeda.

Phases


This report covers around 7+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Lennox-Gastaut Syndrome (LGS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lennox-Gastaut Syndrome (LGS): Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lennox-Gastaut Syndrome (LGS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lennox-Gastaut Syndrome (LGS) drugs.

Lennox-Gastaut Syndrome (LGS) Report Insights

  • Lennox-Gastaut Syndrome (LGS) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Lennox-Gastaut Syndrome (LGS) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Lennox-Gastaut Syndrome (LGS) drugs?
  • How many Lennox-Gastaut Syndrome (LGS) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lennox-Gastaut Syndrome (LGS)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lennox-Gastaut Syndrome (LGS) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lennox-Gastaut Syndrome (LGS) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Takeda
  • Zogenix
  • Marinus Pharmaceuticals
  • SK biopharmaceuticals
  • CuroNZ
  • TAHO Pharmaceuticals
  • Axium Pharmaceuticals

Key Products

  • Soticlestat
  • Fenfluramine
  • Ganaxolone
  • Carisbamate
  • NRP 2945
  • TAH-6601
  • Lorazepam


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Axium Pharmaceuticals
  • CuroNZ
  • Marinus Pharmaceuticals
  • SK biopharmaceuticals
  • TAHO Pharmaceuticals
  • Takeda
  • MORE
Introduction

Executive Summary

Lennox-Gastaut Syndrome (LGS): Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Lennox-Gastaut Syndrome (LGS) - Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis
Soticlestat: Takeda
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Ganaxolone: Marinus Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
NRP 2945: CuroNZ
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical/Discovery Stage Products
  • Comparative Analysis
TAH-6601: TAHO Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Lennox-Gastaut Syndrome (LGS) Key Companies

Lennox-Gastaut Syndrome (LGS) Key Products

Lennox-Gastaut Syndrome (LGS)- Unmet Needs

Lennox-Gastaut Syndrome (LGS)- Market Drivers and Barriers

Lennox-Gastaut Syndrome (LGS)- Future Perspectives and Conclusion

Lennox-Gastaut Syndrome (LGS) Analyst Views

Appendix

List of Tables
Table 1 Total Products for Lennox-Gastaut Syndrome (LGS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Lennox-Gastaut Syndrome (LGS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Takeda
  • Zogenix
  • Marinus Pharmaceuticals
  • SK biopharmaceuticals
  • CuroNZ
  • TAHO Pharmaceuticals
  • Axium Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll